
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$73.61
−$1.25 · -1.67%
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Previous close
$73.61
−$1.25 · -1.67%
Regular session · ET · Market data may be delayed.
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Day range
Current $73.61
52-week range
Current $73.61
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
71
Undervalued
Sentiment
71
Bullish
Risk
31
Moderate Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Day range
Current $73.61
52-week range
Current $73.61
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 249.6M USD | 219.86M USD | 193.48M USD | 161.65M USD | 154.42M USD |
| Cost of goods sold | 71.06M USD | 68.96M USD | 66.44M USD | 56.76M USD | 53.04M USD |
| Gross profit | 178.54M USD | 150.9M USD | 127.05M USD | 104.9M USD | 101.38M USD |
| Research and development | 14.14M USD | 15.65M USD | 16.97M USD | 13.29M USD | 11.8M USD |
| Selling, general, and administrative | 96.49M USD | 83M USD | 72.89M USD | 61.67M USD | 53.16M USD |
| Operating expenses | 110.63M USD | 98.65M USD | 90.34M USD | 78.07M USD | 64.96M USD |
| Interest income | 13.09M USD | 4.95M USD | 3.08M USD | 986K USD | 197K USD |
| Interest expense | 5.18M USD | 205K USD | — | — | 2.22M USD |
| Depreciation and amortization | 10.42M USD | 9.67M USD | 9.52M USD | 9.43M USD | 11.07M USD |
| Operating income | 67.91M USD | 52.26M USD | 36.71M USD | 26.83M USD | 36.43M USD |
| Net income | 57.73M USD | 44.04M USD | 30.11M USD | 20.64M USD | 26.91M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$97.00
31.78% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR94.31M0.10%98.7B USD0.06%$131.25-2.53%
First Trust SMID Cap Rising Dividend Achievers ETFSDVY77.62M0.73%10.66B USD0.58%$40.42-1.73%
Vanguard Morningstar Total Stock Market ETFVTI44.6M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM42.85M0.06%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF19.69M0.02%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO15.39M0.12%12.73B USD0.24%$320.43-3.57%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM14.45M0.09%15.29B USD0.03%$50.99-2.58%
iShares S&P Small-Cap 600 Growth ETFIJT14.08M0.20%6.9B USD0.18%$153.65-2.69%
iShares Core S&P Small-Cap ETFIJR
First Trust SMID Cap Rising Dividend Achievers ETFSDVY
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
iShares S&P Small-Cap 600 Growth ETFIJTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.